Georgios P. Georghiou

Dr. Georgios P. Georghiou

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2025 in Medicina
Verified
Journal Article
Open access
PDF file
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
PGPanos Georghiou
Panos Georghiou
AGAmalia Georgiou
Amalia Georgiou
FTFilippos Triposkiadis
Filippos Triposkiadis
Background: Postoperative atrial fibrillation (POAF) is the most frequent arrhythmic complication following cardiac surgery, affecting nearly 20–30% of patients. While conventional risk factors such as age, hypertension, and atrial enlargement are well known, emerging evidence suggests that cancer itself constitutes a significant, yet underrecognized, contributor to POAF risk. Objective: This review aims to systematically examine the association of cancer with POAF, explore underlying pathophysiological mechanisms, and discuss clinical implications for risk stratification and management in cardiac surgical patients with concurrent or historical malignancies. Methods: A comprehensive review of recent literature was conducted using PubMed and Scopus databases. Studies focusing on the epidemiology, mechanisms, and clinical management of POAF in patients with cancer were evaluated. AI-assisted tools (OpenAI’s ChatGPT) were used for formatting the graphical Results: Lung, breast, gastrointestinal, hematologic, and prostate cancers demonstrate the strongest association with POAF. The arrhythmogenic mechanisms include systemic inflammation, hypercoagulability, direct cardiotoxicity from cancer therapies, autonomic dysregulation, and paraneoplastic syndromes. Integration of oncologic variables into perioperative cardiovascular care is essential for precision risk assessment and outcome optimization. In a recent prospective cardiac surgery cohort, active or historical cancer independently conferred ~4-fold higher odds of POAF (adjusted OR: 3.85, 95% CI: 1.54–9.66), with cancer present in 15% of POAF cases versus 4% of non-POAF patients. Conclusions: Cancer represents a pivotal and multifactorial risk factor for POAF after cardiac surgery. Recognizing its role calls for a multidisciplinary approach that aligns oncologic and cardiovascular care to mitigate arrhythmic risk and improve surgical outcomes.

1 October 2009 in Asian Cardiovascular and Thoracic Annals
Verified
Journal Article
Closed access
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
EPEyal Porat
Eyal Porat
AFAvi Fuks
Avi Fuks
BVBernardo A Vidne
Bernardo A Vidne
MSMilton Saute
Milton Saute
Delayed-onset pericardial effusion following cardiac surgery can give rise to significant morbidity due to its presentation as well as management by traditional surgical techniques. An institutional experience of a video-assisted thoracoscopic technique to create a pericardial window, with the advantages of a minimally invasive approach combined with excellent visualization in such patients, was reviewed. A retrospective analysis was conducted on all patients undergoing video-assisted thoracoscopic for delayed pericardial effusion after cardiac surgery from January 2001 to January 2006 at our center. Seven patients with echocardiographically diagnosed delayed tamponade underwent video-assisted thoracoscopy; 5 were receiving anticoagulants after valve replacement, and 2 had undergone heart transplantation. Pericardial windows were created under general anesthesia and single-lung ventilation using 2 to 3 trocars. Mean operative time was 45 min. There were no complications of the thoracoscopic technique. Video-assisted thoracoscopic creation of a pericardial window is safe and effective treatment for loculated pericardial effusions secondary to cardiac surgery.

20 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
Andrew XanthopoulosAndrew Xanthopoulos
Andrew Xanthopoulos
GKGeorge Kanellopoulos
George Kanellopoulos
PGPanos Georghiou
Panos Georghiou
AGAmalia Georgiou
Amalia Georgiou
FTFilippos Triposkiadis
Filippos Triposkiadis
Background/Objectives: Postoperative atrial fibrillation (POAF) occurs frequently after cardiac surgery and is associated with increased morbidity and mortality. The pathogenesis of POAF in this setting is complex and not completely understood. Since cancer is a well-known risk factor for AF, the aim of this study was to identify potential predictors, including cancer, of POAF after cardiac surgery. Methods: This prospective study included 400 consecutive patients in sinus rhythm who underwent elective cardiac surgery in Aretaeio Hospital (Nicosia, Cyprus) from January 2020 till January 2023. The primary outcome was the development of POAF during hospitalization, defined as any documented AF episode lasting >30 s. Predictors of the primary outcome were studied using univariable and multivariable logistic regression analysis. Results: Of the 400 patients (68 [61–73] years, 64 [16%] females) studied, 66 (16.5%) developed POAF. Among the variables examined, the only predictors of POAF were cardiopulmonary bypass time (odds ratio [OR] = 1.001, 95% confidence interval = [95% CI, 1.000–1.001], p = −0.031) and cancer (OR = 3.852, 95% CI = [1.535–9.664], p = 0.004). Cancer was present in 13 (4%) and in 10 (15%) of patients without and with POAF, respectively (p < 0.001). Conclusions: Cancer was associated with a dramatic increase in POAF risk early after elective cardiac surgery in this study. Whether patients developing POAF after cardiac surgery should be searched for cancer deserves further investigation.
1

1 June 2010 in Asian Cardiovascular and Thoracic Annals
Verified
Journal Article
Closed access
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
BVBernardo A Vidne
Bernardo A Vidne
GSGideon Sahar
Gideon Sahar
ESErez Sharoni
Erez Sharoni
AFAvi Fuks
Avi Fuks
EPEyal Porat
Eyal Porat
To assess the prevalence, characteristics, and outcome of surgical treatment of primary cardiac valve tumors in a single center, we reviewed our experience in 6 women and 1 man, aged 49 to 76 years (mean, 64.7 years) who presented between 1999 and 2006. In one patient, the diagnosis of cardiac valve tumor was made incidentally on transesophageal echocardiography during aortocoronary bypass surgery. The others had clinical symptoms: angina or myocardial infarction in 3, congestive heart failure in 2, dyspnea and cerebrovascular ischemia in 1 patient each. Four of the 7 tumors were benign, and 3 were malignant. All patients survived the operation and recovered uneventfully. Midterm follow-up was available in all patients. Two patients with malignant tumors were considered unsuitable for adjuvant therapy by the oncologist; both died during follow-up from local tumor recurrence. All 5 survivors were categorized at the last follow-up as functional class I, with normal exercise tolerance. Excellent early and midterm surgical results can be obtained in patients with benign cardiac valve tumors, but the prognosis for those with a malignant tumor is poor.

Verified
Journal Article
Open access
PDF file
PGPanos Georghiou
Panos Georghiou
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
Cristiano AmarelliCristiano Amarelli
Cristiano Amarelli
MBMarius Berman
Marius Berman
Heart transplantation is still the definitive therapy for end-stage heart failure, yet the persistent shortage of suitable donor organs limits its application. Traditionally, static cold storage (SCS) has served as an effective standard preservation method, providing safe and adequate protection for preservation times under four hours. Yet, the need to extend this window and the specific metabolic requirements of donation after circulatory death (DCD) hearts have prompted interest in machine perfusion (MP) technologies. This literature review investigates the influence of temperature in ex situ heart perfusion, comparing normothermic (NMP), hypothermic (HMP), and subnormothermic (SNMP) strategies. Evidence from experimental models and emerging clinical studies suggests that MP can prolong preservation times, mitigate ischemic injury, and enable real-time metabolic and viability assessment of donor hearts prior to transplantation. These strategies represent a central trade-off: NMP enables real-time functional assessment of the beating heart, while HMP and SNMP approaches prioritize profound metabolic suppression to mitigate ischemic injury. Nonetheless, current data are limited by high costs, significant resource requirements, variability in perfusion protocols, and the scarcity of randomized controlled trials, particularly for HMP and SNMP. Standardization of methodologies, direct comparative studies, and the adoption of a risk-stratified preservation ecosystem are needed to clarify optimal temperature strategies. However, recent clinical successes with hypothermic strategies in traditionally normothermia-dependent donor types, such as DCD hearts, signal a potential paradigm shift, challenging established value propositions and prompting a critical re-evaluation of optimal preservation strategies.

1 May 2024 in Journal of Biomedical Research & Environmental Sciences
Verified
Journal Article
Closed access
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
PGPanos Georghiou
Panos Georghiou
AGAmalia Georghiou
Amalia Georghiou
AXAndrew Xanthopoulos
Andrew Xanthopoulos
CLConstantinos Lambropoulos
Constantinos Lambropoulos
TFTriposkiadis Filippos
Triposkiadis Filippos
This Narrative Review presents data describing the health burden of Cardiovascular Disease (CVD) within and across the WHO European Region. CVD remains the most common cause of death in the region. Large disparities in data coverage and in country-level morbidity, treatment outcomes and mortality from CVD exist across Europe. Cardiovascular Diseases (CVD) are the leading cause of death in the European Union (EU) [1]. They cover a broad spectrum of medical disorders that affect the circulatory system (the heart and blood vessels), with atherosclerotic CVD (ASCVD) representing most of the cases. ASCVD is characterized by the abnormal build-up of plaques made of, among other constituents, cholesterol or fatty substances and deposited on the inside walls of a person's arteries. Some of the most devastating manifestations of ASCVD include sudden cardiac death [2], myocardial infarction (heart attack) [3], and stroke (loss of focal neurological function due to infarction or hemorrhage in the relevant part of the brain, retina, or spinal cord) [4]. The COVID-19 pandemic placed unprecedented stress on healthcare systems across the world, and the pandemic severely disrupted medical care for CVD patients and exacerbated cardiovascular-related risk factors [5,6]. The need to increase surge capacity for acute and intensive care beds, combined with the need to prioritize the use of personnel and personal protective equipment for COVID-19 patients led to modifications in regular service provision [7]. Some services were curtailed/postponed due to the number of COVID-19 patients and staff shortages occurred within hospitals and day care centers due to infection/quarantine procedures. Further, patients' access to medical services was hindered due to their own infection/quarantine as well as lockdown or travel restrictions. Existing studies have shown dramatic changes in CVD mortality during the pandemic and a persistent threat may have long-term effects on patients with CVD [8]. The development and implementation of evidence-based preventive and treatment approaches must be supported in all countries by consistent surveillance and monitoring, such that we can quantify the health burden of CVD as well as target interventions and provide impetus for action across Europe.